Spots Global Cancer Trial Database for minimal toxicity
Every month we try and update this database with for minimal toxicity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | NCT03940196 | Ovarian Cancer | NovoTTF-100L(O) Paclitaxel | 18 Years - | NovoCure Ltd. | |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT00916409 | Glioblastoma Mu... | NovoTTF-100A de... Temozolomide | 18 Years - | NovoCure Ltd. | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer | NCT04892472 | Non-small Cell ... | NovoTTF-200T Pembrolizumab (... | 22 Years - | NovoCure Ltd. | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) | NCT03940196 | Ovarian Cancer | NovoTTF-100L(O) Paclitaxel | 18 Years - | NovoCure Ltd. | |
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | NCT02831959 | Brain Metastase... | NovoTTF-200M de... Best Standard o... | 18 Years - | NovoCure Ltd. | |
| Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) | NCT02973789 | Nonsmall Cell L... NSCLC | NovoTTF-200T Immune checkpoi... | 22 Years - | NovoCure Ltd. | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | NCT02397928 | Malignant Pleur... | NovoTTF-100L de... Pemetrexed Cisplatin or Ca... | 18 Years - | NovoCure Ltd. | |
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | NCT02831959 | Brain Metastase... | NovoTTF-200M de... Best Standard o... | 18 Years - | NovoCure Ltd. | |
| Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | NCT01756729 | Recurrent Gliob... | NovoTTF-100A | 22 Years - | NovoCure Ltd. | |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) | NCT03377491 | Pancreas Adenoc... | NovoTTF-200T Gemcitabine nab paclitaxel | 18 Years - | NovoCure Ltd. | |
| Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR) | NCT02397928 | Malignant Pleur... | NovoTTF-100L de... Pemetrexed Cisplatin or Ca... | 18 Years - | NovoCure Ltd. | |
| Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | NCT04281576 | Gastric Cancer GastroEsophagea... | NovoTTF-100L(P) Oxaliplatin Capecitabine Trastuzumab | 18 Years - | NovoCure Ltd. | |
| Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | NCT00379470 | Recurrent Gliob... | NovoTTF-100A | 18 Years - | NovoCure Ltd. | |
| Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) | NCT01172548 | Gastrointestina... | imatinib mesyla... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
